Naturally Splendid Enterprises Ltd. (TSXV:NSP) announced that its wholly owned subsidiary Naturally Splendid USA has entered into an exclusive sales and distribution agreement with Medropharm GmbH, a biotech company located in Switzerland.

As quoted in the press release:


Medropharm specializes in the production, extraction, research, and formulation of raw materials and products derived from industrial hemp. Under the Agreement, Naturally Splendid USA will have the exclusive rights to market and distribute in North America an edible, cannabidiol-rich, hemp powder, as well as the non-exclusive rights to market and distribute hemp-derived cannabinoid extracts and formulations globally. The products contain naturally-occurring cannabidiol, a non-psychoactive cannabinoid prevalent in industrial hemp strains of Cannabis sativa. The term of the initial exclusive Distribution Agreement is for two (2) years. Pursuant to the agreement, Naturally Splendid will be permitted to sell the products to Medropharm’s existing clients. Naturally Splendid is required to purchase 2,000kg of the hemp powder in the first year and 3,000kg in the following years to accommodate Medropharm’s existing product demands as well as NSE’s own industry prospects.

Medropharm’s industrial hemp is sustainably grown on over 3,500 hectares under strict EU Regulations with constant monitoring to minimize the environmental impact and ensure the highest quality of raw materials. From seed through product development, the raw materials are analyzed to ensure consistency in quality, safety and composition. The products are manufactured and tested in facilities with FDA, ISO, and cGMP certifications which is rare find in this burgeoning industry.

Craig Goodwin, CEO of Naturally Splendid, commented:

Naturally Splendid is thrilled to have found a partner like Medropharm with a similar focus on quality and accountability. We are most fortunate to start this exclusive distribution agreement with Medropharm as it allows us to continue sales of the Medropharm products in the United States to clients that previously purchased the products from Medropharm directly. It is our intention to build on that existing clientele and increase sales volumes significantly. We remain committed to maximizing the multiple revenue streams available from this one amazing plant.

Patrick Widmer, CEO of Medropharm, commented:

We are delighted to partner with Naturally Splendid for high-volume distribution of our hemp-derived products. We share the same strategy focused on creating an industry standard for transparency and quality for our consumers. Our cultivation and inventory are sufficient to allow Naturally Splendid to generate annual sales of our cannabidiol (CBD) products at approximately US $10,000,000. We are confident that Naturally Splendid, through focused efforts, can grow annual sales of the products to ten (10) tons annually in the United States as the regulatory environment continues to evolve. There are many exciting future opportunities on the horizon for our partnership with Naturally Splendid and we look forward to a prosperous relationship.

Click here to read the Naturally Splendid Enterprises Ltd. (TSXV:NSP) press release

Click here to see the Naturally Splendid Enterprises Ltd. (TSXV:NSP) profile.

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less